• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Core Facilities

High-Throughput Polymorphism Detection

References

Collaboration of Harvard Investigators at the Brigham and Women’s Hospital (Jing Ma, Graham Colditz, David Hunter, Frank Spiezer), the School of Public Health (Ed Giovannucci), and Harvard Medical School (Sue Hankinson) in the NCI Breast and Prostate Cancer Cohort Consortium.  This Consortium links the Nurses’ Health Study, Health Professionals Study, Physicians’ Health Study, and Womens’ Health Study cohorts with cohorts at USC, NCI, ACS, and IARC, and genomics groups at the Whitehead Institute and CEPH.  Haplotypes in 53 candidate genes for breast and prostate cancer will be established, tested for association with these outcomes, and examined for gene-environment interactions.  In all, over 100 SNPs will be assayed on 5,000 DNA samples.

Collaborating with DF/HCC investigators in genomics and utilizing the resources of the DF/HCC High-Throughput Polymorphism Detection Core (David Hunter, Director), DF/HCC Epidemiologists (Drs. Fuchs (DFCI), Chan (MGH), Giovannucci (HSPH), Colditz (BWH)) are examining whether pharmacogenomic profiles may influence the response to aspirin chemoprevention.  Utilizing banked DNA specimens from 1062 women in the Nurses’ Health Study, we found that among women with variant genotypes of UDP-glucuronosylyltransferase 1A6 (UGT1A6), the major enzyme in glucuronidation of aspirin, (50% of the population) experienced a substantial reduction in adenoma risk when consuming aspirin, whereas women with wild-type genotypes did not experience any reduction in risk with regular aspirin use (Chan et al, J Natl Cancer Inst, 2004, in press).  These findings are consistent with data that aspirin’s anti-neoplastic effect is dose-dependent and provides proof-of-principle that an individual’s pharmacogenomic profile may influence the response to drug therapy.  We are now conducting larger studies to confirm these findings and to evaluate a possible role for genetic polymorphisms in tailoring an approach to colorectal cancer prevention.  Furthermore, additional studies will address whether UGT1A6 genotype modifies the other potential benefits of aspirin or its potential hazards.

Notable References:

  1. Cramer DW, Hornstein MD, McShane P, Powers RD, Lescault PJ, Vitonis AF, De Vivo I. Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. Am J Obstet Gynecol. 2003 Oct;189(4):1085-92.
  2. Terry KL, Titus-Ernstoff L, Garner EO, Vitonis AF, Cramer DW. Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk.  Cancer Epidemiol Biomarkers Prev 2003 Mar;12(3):187-90
  3. Gong M N, Sai Y, Zhou W, Thompson B T, Xu LL, and Christiani D C. Genotyping patients with recent blood transfusions. Epidemiology, Nov 2003; 14(6): 744-7.
  4. Egan KM, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Mignone LI, Farin F, Hunter DJ.  Association of NAT2 and smoking in relation to breast cancer incidence in a population-based case-control study (United States).  Cancer Causes Control 2003 Feb;14(1):43-51
  5. Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ, Byrne C.  Polymorphisms in steroid hormone pathway genes and mammographic density.  Breast Cancer Res Treat 2003 Jan;77(1):27-36